The estimated Net Worth of Stewart Abbot is at least $252 Tisíc dollars as of 15 May 2018. Stewart Abbot owns over 21,054 units of Fate Therapeutics Inc stock worth over $251,878 and over the last 9 years Stewart sold FATE stock worth over $0.
Stewart has made over 1 trades of the Fate Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Stewart exercised 21,054 units of FATE stock worth $139,377 on 15 May 2018.
The largest trade Stewart's ever made was exercising 21,054 units of Fate Therapeutics Inc stock on 15 May 2018 worth over $139,377. On average, Stewart trades about 3,008 units every 0 days since 2015. As of 15 May 2018 Stewart still owns at least 64,917 units of Fate Therapeutics Inc stock.
You can see the complete history of Stewart Abbot stock trades at the bottom of the page.
Stewart's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... a Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: